Real-World Data Study Explores Duration and Efficacy of Checkpoint Inhibitors in Skin Cancer

In a recently published paper in Cancers, researchers used real-world data (RWD) to investigate the efficacy of first-line checkpoint inhibitor treatment for cutaneous squamous cell carcinoma (cSCC) and the durability of the response. The data, taken from 39 patients receiving treatment at one of eight cancer centers in Germany, shows all most half of patients had a tumor response, with a median progression-free survival rate of 29 months.

According to Maggie L. Shaw, “Twenty percent of patients overall experienced durable remissions, with checkpoint inhibitor treatment also having a positive impact against tumors in patients who have autoimmune conditions and lymphoproliferative disorders—although to a lesser extent and ultimately resulting in shortened OS.”

To read more, click here.

(Source: AJMC¸ December 10^th, 2022)